Key Points
- Christian Henry sold 12,497 PACB shares on March 3 at an average price of $1.51 for about $18,870, leaving him with 3,581,813 shares (a 0.35% reduction in his position).
- PACB shares trade at $1.51 with a market cap of about $456 million, a negative P/E, a 52‑week range of $0.85–$2.73, and the company reported Q4 EPS of -$0.12 (beating estimates) on revenue of $44.65 million.
- Analyst sentiment is mixed but leans positive overall, with a consensus rating of "Moderate Buy" and a consensus price target of $2.20.
Pacific Biosciences of California, Inc. (NASDAQ:PACB - Get Free Report) insider Christian Henry sold 12,497 shares of the business's stock in a transaction that occurred on Tuesday, March 3rd. The stock was sold at an average price of $1.51, for a total value of $18,870.47. Following the completion of the transaction, the insider owned 3,581,813 shares in the company, valued at $5,408,537.63. The trade was a 0.35% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this hyperlink.
Pacific Biosciences of California Stock Performance
Shares of PACB traded down $0.05 on Thursday, reaching $1.51. 2,537,884 shares of the company's stock traded hands, compared to its average volume of 7,547,861. The stock's 50 day simple moving average is $1.96 and its two-hundred day simple moving average is $1.80. The stock has a market cap of $456.02 million, a PE ratio of -0.82 and a beta of 2.31. Pacific Biosciences of California, Inc. has a 52-week low of $0.85 and a 52-week high of $2.73. The company has a current ratio of 5.15, a quick ratio of 4.47 and a debt-to-equity ratio of 120.65.
Pacific Biosciences of California (NASDAQ:PACB - Get Free Report) last announced its quarterly earnings data on Thursday, February 12th. The biotechnology company reported ($0.12) earnings per share (EPS) for the quarter, beating analysts' consensus estimates of ($0.19) by $0.07. Pacific Biosciences of California had a negative return on equity of 326.43% and a negative net margin of 341.47%.The firm had revenue of $44.65 million during the quarter, compared to the consensus estimate of $44.60 million. On average, analysts forecast that Pacific Biosciences of California, Inc. will post -0.72 earnings per share for the current fiscal year.
Institutional Investors Weigh In On Pacific Biosciences of California
Several institutional investors have recently made changes to their positions in PACB. ProShare Advisors LLC boosted its holdings in shares of Pacific Biosciences of California by 10.2% during the fourth quarter. ProShare Advisors LLC now owns 63,799 shares of the biotechnology company's stock worth $119,000 after purchasing an additional 5,883 shares during the period. Intech Investment Management LLC increased its holdings in Pacific Biosciences of California by 5.2% during the 3rd quarter. Intech Investment Management LLC now owns 132,368 shares of the biotechnology company's stock valued at $169,000 after purchasing an additional 6,564 shares during the period. Mercer Global Advisors Inc. ADV raised its position in Pacific Biosciences of California by 47.9% during the 4th quarter. Mercer Global Advisors Inc. ADV now owns 20,663 shares of the biotechnology company's stock valued at $39,000 after purchasing an additional 6,695 shares during the last quarter. Rhumbline Advisers lifted its holdings in Pacific Biosciences of California by 2.1% in the 3rd quarter. Rhumbline Advisers now owns 415,679 shares of the biotechnology company's stock worth $532,000 after buying an additional 8,532 shares during the period. Finally, Green Alpha Advisors LLC grew its position in shares of Pacific Biosciences of California by 5.4% in the 4th quarter. Green Alpha Advisors LLC now owns 183,466 shares of the biotechnology company's stock worth $343,000 after buying an additional 9,441 shares during the last quarter.
Analyst Ratings Changes
Several analysts have commented on PACB shares. Barclays lifted their price objective on shares of Pacific Biosciences of California from $1.50 to $2.00 and gave the stock an "equal weight" rating in a research report on Monday, December 15th. Stephens upped their price objective on Pacific Biosciences of California from $1.80 to $2.00 and gave the company an "overweight" rating in a research note on Monday, November 10th. Piper Sandler raised their target price on Pacific Biosciences of California from $1.50 to $2.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 11th. Weiss Ratings restated a "sell (e+)" rating on shares of Pacific Biosciences of California in a research note on Thursday, January 22nd. Finally, Zacks Research upgraded Pacific Biosciences of California from a "hold" rating to a "strong-buy" rating in a research note on Thursday, February 19th. One research analyst has rated the stock with a Strong Buy rating, three have issued a Buy rating, two have assigned a Hold rating and one has given a Sell rating to the company's stock. According to data from MarketBeat.com, the company currently has a consensus rating of "Moderate Buy" and a consensus price target of $2.20.
View Our Latest Research Report on Pacific Biosciences of California
Pacific Biosciences of California Company Profile
(
Get Free Report)
Pacific Biosciences of California, Inc develops, manufactures and sells high-performance DNA sequencing systems for genetic and genomic analysis. The company's proprietary single-molecule, real-time (SMRT) sequencing technology is designed to enable long-read sequencing, offering high accuracy for applications such as de novo genome assembly, transcriptome characterization and structural variation analysis. Pacific Biosciences markets a suite of instruments, including the Sequel and Sequel IIe systems, alongside reagents, consumables and data analysis software to support a range of life science research.
Founded in 2004 and headquartered in Menlo Park, California, Pacific Biosciences has expanded its global reach by serving academic institutions, biotechnology and pharmaceutical companies, and government research centers across North America, Europe and Asia.
Further Reading
This instant news alert was generated by narrative science technology and financial data from InsiderTrades.com in order to provide readers with the fastest and most accurate reporting. Please send any questions or comments about this story to [email protected].
